Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%.
Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial
Outlook’s Lytenava is a recombinant monoclonal antibody that binds and blocks vascular endothelial growth factor (VEGF) thereby reducing endothelial cell proliferation, vascular leakage, and new
November 27, 2024